VacciTalks: Vaccine Development from Bench to Patient: Myths and Reality 

Joe is board certified in paediatrics, infectious diseases, microbiology, and epidemiology and held a chair as professor of vaccine development at the Gutenberg University, Mainz, Germany.

Joe’s clinical studies were cornerstones for global licenses of acellular pertussis and respective combination vaccines.  Joe was a member (1995-2007) and chair of the German vaccination advisory board (STIKO) for 3 consecutive terms (1997-2007) and advisor to the Paul Ehrlich Institute (PEI) and different WHO committees, including SAGE and the GACVS-groups. He was the Global Head, Medical Affairs with Novartis Vaccines during the time of the influenza pandemic (about 2010) and he joined Pfizer in 2011 and was Vice President for Medical-, Developmental-, Scientific- and Clinical-Affairs (MDSCA) and Global Lead Viral Vaccines until May 2021.  

Currently, Joe is Editor-in-Chief with Global Health Press (GHP) in Singapore and he is also Strategic and Scientific Advisor with “Vaccelerate” at the Cologne University, Germany. 

A vaccine expert with more than 30 years of experience, Bernd has been responsible for a range of global pricing and market access initiatives for vaccines in the international pharmaceutical companies — from delivering a range of solutions across development and strategic market access considerations for trial design to value demonstration in P&R negotiations as well as commercialization strategies.  

Kenny’s background covers a wide array of indications across pharma, medical devices, and digital health. He has multiple years of experience in clinical trial operations and management and offers a unique perspective on the clinical development lifecycle from generating a comprehensive strategy through executing a successful trial.